Exclusive Summary

• - Off-patent pyronaridine molecule with low global IP barriers for injection, enabling rapid multi-country market entry.
• - Malaria causes ~249 million cases and ~608k deaths annually worldwide; a clear hospital/ED segment cannot take oral therapy, favoring injectables.
• - WHO recognizes pyronaridine–artesunate as an ACT option (oral); this injection monotherapy is not standard first-line and should be positioned as a bridge/adjunct before completing an oral ACT.
• - Very limited global supply of pyronaridine injections and low competition, ideal for hospital differentiation and combo supply with ACTs.
• - Mature process and controllable COGS allow meaningful price leverage versus branded ACTs/imported injectables, supporting provincial/hospital tenders.